Literature DB >> 10971577

Expression and characterization of Edg-1 receptors in rat cardiomyocytes: calcium deregulation in response to sphingosine 1-phosphate.

N Nakajima1, A L Cavalli, D Biral, C C Glembotski, P M McDonough, P D Ho, R Betto, D Sandoná, P T Palade, C A Dettbarn, R E Klepper, R A Sabbadini.   

Abstract

Recent evidence indicates that sphingolipids are produced by the heart during hypoxic stress and by blood platelets during thrombus formation. It is therefore possible that sphingolipids may influence heart cell function by interacting with G-protein-coupled receptors of the Edg family. In the present study, it was found that sphingosine 1-phosphate (Sph1P), the prototypical ligand for Edg receptors, produced calcium overload in rat cardiomyocytes. The cDNA for Edg-1 was cloned from rat cardiomyocytes and, when transfected in an antisense orientation, effectively blocked Edg-1 protein expression and reduced the Sph1P-mediated calcium deregulation. Taken together, these results demonstrate that cardiomyocytes express an extracellular lipid-sensitive receptorsystem that can respond to sphingolipid mediators. Because the major source of Sph1P is from blood platelets, we speculate that Edg-mediated Sph1P negative inotropic and cardiotoxic effects may play important roles in acute myocardial ischemia where Sph1P levels are probably elevated in response to thrombus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10971577     DOI: 10.1046/j.1432-1327.2000.01656.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  14 in total

1.  Chasing sphingosine-1-phosphate, a lipid mediator for cardiomyocyte survival.

Authors:  Qinglin Yang
Journal:  Cardiovasc Res       Date:  2007-02-12       Impact factor: 10.787

2.  Pharmacological pre- and post-conditioning with the sphingosine-1-phosphate receptor modulator FTY720 after myocardial ischaemia-reperfusion.

Authors:  U Hofmann; K Hu; F Walter; N Burkard; G Ertl; J Bauersachs; O Ritter; S Frantz; A Bonz
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 3.  Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress.

Authors:  Joel S Karliner
Journal:  Biochim Biophys Acta       Date:  2012-06-23

Review 4.  Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites.

Authors:  Astrid E Alewijnse; Stephan L M Peters; Martin C Michel
Journal:  Br J Pharmacol       Date:  2004-10-25       Impact factor: 8.739

5.  A sphingosine-1-phosphate-activated calcium channel controlling vascular smooth muscle cell motility.

Authors:  Shang-Zhong Xu; Katsuhiko Muraki; Fanning Zeng; Jing Li; Piruthivi Sukumar; Samir Shah; Alexandra M Dedman; Philippa K Flemming; Damian McHugh; Jacqueline Naylor; Alex Cheong; Alan N Bateson; Christopher M Munsch; Karen E Porter; David J Beech
Journal:  Circ Res       Date:  2006-05-04       Impact factor: 17.367

6.  Sphingosine kinase activity is required for sphingosine-mediated phospholipase D activation in C2C12 myoblasts.

Authors:  Elisabetta Meacci; Francesca Cencetti; Chiara Donati; Francesca Nuti; Laura Becciolini; Paola Bruni
Journal:  Biochem J       Date:  2004-08-01       Impact factor: 3.857

7.  VEGF induces S1P1 receptors in endothelial cells: Implications for cross-talk between sphingolipid and growth factor receptors.

Authors:  Junsuke Igarashi; Phillip A Erwin; Ana Paula V Dantas; Hongjie Chen; Thomas Michel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-08       Impact factor: 11.205

8.  Cardiomyocyte S1P1 receptor-mediated extracellular signal-related kinase signaling and desensitization.

Authors:  Rong Tao; Holly E Hoover; Jianqing Zhang; Norman Honbo; Conrad C Alano; Joel S Karliner
Journal:  J Cardiovasc Pharmacol       Date:  2009-06       Impact factor: 3.105

Review 9.  Sphingosine kinase and sphingosine 1-phosphate in cardioprotection.

Authors:  Joel S Karliner
Journal:  J Cardiovasc Pharmacol       Date:  2009-03       Impact factor: 3.105

Review 10.  The p21-activated kinase 1 (Pak1) signalling pathway in cardiac disease: from mechanistic study to therapeutic exploration.

Authors:  Yanwen Wang; Shunyao Wang; Ming Lei; Mark Boyett; Hoyee Tsui; Wei Liu; Xin Wang
Journal:  Br J Pharmacol       Date:  2017-06-28       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.